Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Subjects

Subjects :

Adenine analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
Humans
Lymphoma, B-Cell pathology
Piperidines
Prognosis
Lymphoma, B-Cell drug therapy
Protein Kinase Inhibitors therapeutic use
Protein-Tyrosine Kinases antagonists & inhibitors
Pyrazoles therapeutic use
Pyrimidines therapeutic use

Details

Language :

English

ISSN :

1527-7755

Volume :

31

Issue :

1

Database :

MEDLINE

Journal :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

23045586

Full Text :

https://doi.org/10.1200/JCO.2012.44.4281